NervGen Pharma Corporation (QB) (NGENF)

NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium

Adam Rogers, MD, President and Chief Executive Officer of NervGen to present and discuss clinical data from the...

NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury

VANCOUVER, British Columbia, Feb. 09, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the...

NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing

VANCOUVER, British Columbia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NervGen Pharma Begins Trading on Nasdaq Today

VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the...

Form EFFECT - Notice of Effectiveness

Form CERT - Certification by an exchange approving securities for listing

Form 8-A12B - Registration of securities [Section 12(b)]

Form F-10/A - Registration Statement for Securities of certain Canadian Issuers.: [Amend]

NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB:...

Form F-X - Appointment of Agent for Service of Process and Undertaking

Form F-10 - Registration Statement for Securities of certain Canadian Issuers.

NervGen Pharma Announces Proposed Amendment to Warrants

Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB:...

NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates

Expanded CONNECT SCI Study data demonstrated unprecedented durable improvement in function, independence, and...

NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury

Week 16 follow-up data, coupled with blinded exit interviews conducted up to 364 days after the study period...